🇺🇸 Abobotulinumtoxin A in United States
15 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 15
Most-reported reactions
- Eyelid Ptosis — 3 reports (20%)
- Dysphagia — 2 reports (13.33%)
- Fatigue — 2 reports (13.33%)
- Muscular Weakness — 2 reports (13.33%)
- Abortion Spontaneous — 1 report (6.67%)
- Drug Exposure During Pregnancy — 1 report (6.67%)
- Drug Ineffective — 1 report (6.67%)
- Dry Mouth — 1 report (6.67%)
- Dysphonia — 1 report (6.67%)
- Dyspnoea — 1 report (6.67%)
Other Neurology approved in United States
Frequently asked questions
Is Abobotulinumtoxin A approved in United States?
Abobotulinumtoxin A does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Abobotulinumtoxin A in United States?
Neurology Center of New England P.C. is the originator. The local marketing authorisation holder may differ — check the official source linked above.